AbbVie’s Skyrizi yields to UCB’s Bimzelx in psoriatic arthritis head‑to‑head trial on May 20, 2026 AbbVie ACR50 Arthritis, Psoriatic Bacterial Endocarditis bimekizumab Bimzelx bleomycin/dacarbazine/lomustine/vincristine Phase III Prostate-Specific Antigen risankizumab Skyrizi Standard of Care UCB +